Last reviewed · How we verify
Elucirem
At a glance
| Generic name | Elucirem |
|---|---|
| Also known as | gadopiclenol |
| Sponsor | Guerbet |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Detect and visualize lesions with abnormal vascularity with MRI
Common side effects
- Injection site pain
- Headache
- Nausea
- Injection site warmth
- Injection site coldness
- Dizziness
- Localized swelling
- Erythema
- Maculopapular rash
- Vomiting
- Feeling hot
- Pyrexia
Serious adverse events
- Nephrogenic Systemic Fibrosis
- Hypersensitivity Reactions
- Acute pancreatitis
- Acute respiratory distress syndrome
- Pulmonary edema
- Gadolinium-associated plaques
- Worsened renal impairment
- Cystatin C increase
- Blood creatinine increase
Key clinical trials
- Screening for Brain Metastases (PHASE2)
- Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas (PHASE3)
- Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age (PHASE2)
- Gadopiclenol in Contrast Enhanced MRI of the Prostate (PHASE4)
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis (PHASE2)
- High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment (PHASE4)
- Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elucirem CI brief — competitive landscape report
- Elucirem updates RSS · CI watch RSS
- Guerbet portfolio CI